Evidence map›Paper›PMID 25217267›Full record

ReviewSeminars in nephrology2014

Bioengineering kidneys for transplantation.

Maria Lucia L Madariaga, Harald C Ott

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Early-Phase Clinical Trials of Bio-Artificial Organ Technology: A Systematic Review of Ethical Issues.Transplant international : official journal of the European Society for Organ Transplantation · 2022
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Bioartificial Kidneys.Current stem cell reports · 2017
    Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Maria Lucia L MadariagaDivision of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Harvard Stem Cell Institute, Boston, MA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.
Harald C OttDivision of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Harvard Stem Cell Institute, Boston, MA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA. Electronic address: hott@mgh.harvard.edu.
Harvard Stem Cell Institute · USHarvard University · US

Funding

Organ engineering based on perfusion decellularized matrixDP2OD008749 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI OTT, HARALD C · 2011 to 2011
$2.6M
AMELIORATION OF THE DELETERIOUS EFFECTS OF DONOR BRAIN DEATHF32HL117540 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MADARIAGA, MARIA LUCIA · 2013 to 2014
$110k
NHLBI NIH HHS F32 HL117540NHLBI NIH HHS F32HL117540NIH HHS DP2 OD008749NIH HHS DP2OD008749-01
6 · The paper itself

Abstract

One in 10 Americans suffers from chronic kidney disease, and close to 90,000 people die each year from causes related to kidney failure. Patients with end-stage renal disease are faced with two options: hemodialysis or transplantation. Unfortunately, the transplantation option is limited because of the shortage of donor organs and the need for immunosuppression. Bioengineered kidney grafts theoretically present a novel solution to both problems. Herein, we discuss the history of bioengineering organs, the current status of bioengineered kidneys, considerations for the future of the field, and challenges to clinical translation. We hope that by integrating principles of tissue engineering, and stem cell and developmental biology, bioengineered kidney grafts will advance the field of regenerative medicine while meeting a critical clinical need.

Indexed as

KidneyKidney TransplantationBioengineeringHumansKidney Failure, ChronicTissue EngineeringbioengineeringKidneyorgan engineeringperfusion decellularizationtransplantation

Identifiers

PMID25217267
PMCPMC4373354
OpenAlexW1986568443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.